Condition: Non-Muscle Invasive Bladder Neoplasms · Sponsor: Janssen Research & Development, LLC
The purpose of the study in Part 1 (dose escalation) and in Part 2 (dose expansion) is to determine the recommended Phase 2 dose(s) (RP2D\[s\]) and evaluate preliminary clinical efficacy. Part 3 (dose expansion) will confirm safety and preliminary clinical activity at the RP2D. Part 4 (RP2D expansion; MoonRISe-2) will assess the overall complete response (CR) in participants with intermediate-risk-non-muscle invasive bladder cancer (IR-NMIBC; means the cancer cells are only in the bladder's inner lining).
This description comes directly from the study's public registry record.
Study Contact · 844-434-4210 · Participate-In-This-Study1@its.jnj.com
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham - The Kirklin Clinic | Birmingham, Alabama, United States | Recruiting |
| University of Southern California | Los Angeles, California, United States | Recruiting |
| Urology Associates of Denver | Lone Tree, Colorado, United States | Recruiting |
| Urological Research Network | Hialeah, Florida, United States | Recruiting |
| Advanced Urology Institute | Largo, Florida, United States | Recruiting |
| Advent Health Orlando | Orlando, Florida, United States | Completed |
| Advanced Urology Institute 1 | Oxford, Florida, United States | Completed |
| H Lee Moffitt Cancer Center | Tampa, Florida, United States | Recruiting |
| Northwestern University | Chicago, Illinois, United States | Recruiting |
| Associated Urological Specialists | Chicago Ridge, Illinois, United States | Recruiting |
| Urology of Indiana | Greenwood, Indiana, United States | Recruiting |
| Urologic Specialists of Northwest Indiana | Merrillville, Indiana, United States | Recruiting |
+ 47 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05316155